Four strategic takeaways from this year's that are important for pharma oncology leaders.
Maria Whitman
Advertisement
Articles by Maria Whitman
Advertisement
Latest Updated Articles
Beyond the Science: Commercial Implications From ASCO 2017Published: August 21st 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
2
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
3
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
4
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
5
